EyeCool Therapeutics develops treatments that provide rapid, long‑lasting relief for patients with Chronic Ocular Surface Pain (COSP). Their therapy targets the underlying mechanisms of ocular pain to reduce symptoms and improve quality of life, offering a non‑opioid option for a condition with limited existing solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic ocular surface pain (COSP) have limited treatment options, often enduring persistent discomfort despite existing therapies. The condition is under‑addressed in eye care, leading to reduced quality of life and ongoing clinical management challenges.
Solution
EyeCool Therapeutics is developing the ETX‑4143™ system, a non‑invasive device that applies a controlled dose of thermal energy to the ocular surface to alleviate COSP. The technology cools the conjunctiva and the long ciliary nerves located just beneath the sclera, modulating pain pathways without affecting the eye’s sensitive structures. By delivering precise, localized cooling, the system aims to provide rapid onset of relief that persists over time. The device is intended for use in clinical settings under professional supervision, enabling ophthalmologists and optometrists to offer a novel, mechanism‑based therapy for patients who have exhausted conventional treatments.
Target Audience
Primary customers are ophthalmologists, optometrists, and eye care clinics treating patients with chronic ocular surface pain who have not responded to standard therapies.
Features
- Non‑invasive handheld device that delivers calibrated thermal energy to the ocular surface
- Targeted cooling of conjunctival tissue and long ciliary nerves while sparing corneal and intraocular structures
- Precise dose control to ensure consistent therapeutic effect across patients
- Designed for rapid pain relief with sustained efficacy through repeated applications
- Investigational device complying with FDA regulatory warnings and clinical trial protocols